The Agency for Healthcare Research and Quality (AHRQ) and the Centers for Disease Control and Prevention's (CDC) National Office of Public Health Genomics (NOPHG) have released a report examining the evidence for using Cytochrome P450 tests in prescribing selective serotonin reuptake inhibitors (SSRIs) for adults with depression.
The findings of this report are that there is insufficient information to support the use of this testing in clinical practice and that more well designed studies are needed to determine the clinical value for patients and the impact on outcomes. The process for producing this report is based on an exhaustive review of the literature to assess the evidence for analytical validity, clinical validity and clinical utility of the tests. Ethical, legal and social implications related to testing are also included in the assessment. The full report is available online. A news release that summarizes the major findings is also available.